Author of

• 32016

  +

  EP1.08 - Oligometastatic NSCLC (ID 198)

  • Event: WCLC 2019
  • Type: E-Poster Viewing in the Exhibit Hall
  • Track: Oligometastatic NSCLC
  • Presentations: 1
  • Now Available
  • Moderators:
  • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall

  • 32020

    +

    EP1.08-04 - Local Treatment for Patients with Pulmonary Oligo-Recurrence of Non-Small Cell Lung Cancer (Now Available) (ID 2550)

    08:00 - 18:00  |  Author(s): Shuhei Sekii
    • Abstract
    • Slides

    Background
    

    The concept of oligo-recurrence, which is theoretically curable by definitive local therapy, has been proposed in several cancers. But the efficacy of local therapy for patients with pulmonary oligo-recurrence of non-small cell lung cancer (NSCLC) is unclear. The aim of this study was to investigate the efficacy of local therapy for pulmonary oligo-recurrence of NSCLC.

    Method
    

    We retrospectively analyzed the data on 35 patients who underwent lung resection or radiotherapy for pulmonary oligo-recurrence in our institution, between 2000 and 2016. We evaluated independent risk factors for overall survival and progression-free survival after local treatment for patients with pulmonary oligo-recurrence of non-small cell lung cancer. In this study, pulmonary oligo-recurrence was defined as local recurrences limited within lungs after local or systemic treatment for NSCLC.

    Result
    

    There were 26 men and 9 women with median age of 72 years [interquartile range (IQR), 64-75]. The median follow-up time was 48.8 months [IQR, 16.3-66.7]. Previous therapies for NSCLC were pulmonary resections in 26 patients (74.2%), stereotactic radiosurgery for brain metastasis in 3 (8.6%), radiotherapy for lung tumors in 3 (8.6%), chemoradiotherapy in 2 (5.7%) and chemotherapy (ALK-TKI) in 1 (2.9%). The median progression-free interval between previous therapy and local treatment for oligo-recurrence was 29.0 months [IQR, 16.0-44.5]. Histopathology were adenocarcinoma in 26 patients (74.2%), squamous cell carcinoma in 7 (20.0%), adenosquamous carcinoma and large cell neuroendocrine carcinoma in 1 (2.9 %). Among 21 patients (60.0%) who underwent surgical resection for pulmonary oligo-recurrence, surgical procedures were wedge resection in 11 patients, segmentectomy in 3, lobectomy in 5 and pneumonectomy in 2. Among 14 patients (40.0%) who underwent radiotherapy for pulmonary oligo-recurrence, 11 patients (31.4%) underwent stereotactic body radiotherapy. There were no treatment-related death. Three-year overall survival and progression-free survival were 60.3% and 49.6%. Post-treatment recurrence occurred in 16 (60.4%) patients (local; 6, distant; 2, local and distant; 8). Univariate analyses identified progression-free interval between previous therapy and local treatment for pulmonary oligo-recurrence as independent risk factor for overall survival (HR 0.97 [95% CI 0.95-1]; p=0.039).

    Conclusion
    

    Local therapy for pulmonary oligo-recurrence of NSCLC are feasible and the post-therapeutic survival is acceptable. But there are highly selective patients in our study, further study is needed for curative intent treatment.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.